key: cord-1047525-b1jh5nvu
authors: Francque, Sven
title: Top level research in hepatology: COVID-19 and beyond
date: 2021-05-04
journal: JHEP Rep
DOI: 10.1016/j.jhepr.2021.100302
sha: 5bb1788e636802ea518a979cab1c6ee66ed07d5e
doc_id: 1047525
cord_uid: b1jh5nvu
nan
The world is now living with COVID19 for more than a year, with a tremendous impact, not only on our daily life, but undeniably also on health care and research. When the first wave hit the health care system, oncological care was, however, one of the areas of medicine that was felt to be "essential" (whatever that may imply), deemed to be protected and maintained as much as possible. In the current issue of JHEP Reports, S. Muñoz-Martinez et al (1) report on a survey among 76 high volume centres worldwide investigating the impact of the COVID19 pandemic on the care for patients with hepatocellular carcinoma (HCC). The results are cumbersome: more than 80% of the centres made adjustments to the screening program, diagnostic procedures were substantially delayed and although between 60 and 80% of the centres maintained several types of treatment, most of the procedures were rescheduled e.g., over 60% of surgical procedures. Transplant programs were on hold in 44% of the centres. Many centres could continue to include patients in clinical trials, although also that activity was substantially reduced. This data is worrisome, as it is not to be excluded that these changes might have an impact on the long-term outcomes of the HCC patients. The CERO-19 (Liver Cancer Outcome in the COVID-19 pandemic) project continues to collect data that will inform us on these latter issues, but the data presented here should already alarm us and be taken into account when deciding on health policy measures when coping with the successive waves of COVID-19.
In the same issue, Ganne-Carié et al (2) tackle another important issue in HCC, namely aetiology-related differences. In this study, authors focused on HCC that were diagnosed during 6-montly surveillance in patients with cirrhosis related to viral hepatitis, alcohol use or a combination of both as underlying aetiology. A first interesting finding is the lower 5year incidence in those with alcoholic liver disease, compared to viral or mixed aetiology. At diagnosis, tumour burden was comparable between aetiologies, but early BCLC stages were nevertheless less frequent in the alcoholic liver disease group. The latter is explained by the poorer physical condition with more impaired ECOG performance status. Median survival in these cases was lower, but when adjusting for tumour size and ECOG score, as well as Child-Pugh score, there was no aetiology-specific difference, suggesting that the poorer condition of the patients was of more impact than the aetiology as such. Of course, alcohol abuse comes with a psychosocial and nutritional context that needs to be taken into account, besides the specific mechanisms of alcohol toxicity.
The COVID pandemic also has a tremendous impact on daily life, with a risk of weight gain and sedentary behaviour that can further aggravate the problems associated with obesity, including Non-Alcoholic Fatty Liver Disease (NAFLD). The relation between weight and NAFLD is complex. Overweight and obesity are clearly risk factors for NAFLD, and weight loss can induce histological improvement, even in terms of fibrosis regression (3, 4) . But it is not all about weight. Oh et al (5) compared 54 obese Japanese men who participated in a closely supervised aerobic exercise program but did not reduce their caloric intake (they even slightly increased their energy intake) to 24 men who followed a dietary restriction regimen without changing their physical activity level. Both groups improved on non-invasive tests that reflect NAFLD severity, but in the exercise group, weight loss was minimal, and the authors could hence assess by the comparison of the 2 groups the weight-independent effects of exercise. The latter point is crucial, as it pinpoints the added value of this study: several studies have shown already that exercise is beneficial in NAFLD (6), but the methodological rigour of the current study allows addressing specific questions that to date were difficult to reliably answer, and in particular to separate the effect of exercise on weight from weight-loss independent effects that might be introduced by exercise. The authors hereby demonstrate substantial weight loss-independent effects on liver steatosis and liver stiffness, as well as on other parameters like the FibroScan-AST score. The authors furthermore provide mechanistic insights that help explaining the observations, by showing that the improvements in hepatic parameters were closely associated with anthropometric changes, e.g. reduction in adipose tissue and preservation of muscle mass, with increases in muscle strength, reductions in inflammation and oxidative stress and changes in organokine concentrations (such as adiponectin and myostatin) during the exercise regimen. This all stresses the importance of the adipose tissue-muscle-liver interaction in NAFLD pathogenesis that goes far beyond a simplistic view on body weight as a driver of NAFLD (3, 4) .
The search for a pharmacological treatment for NAFLD, focusing on the more severe subtype of Non-Alcoholic Steatohepatitis (NASH) with some degree of fibrosis, is paved with many difficulties. The complexity of disease pathophysiology is amongst one of the main reasons that to date no drug has specifically been approved for the treatment of NASH, and several trials recently failed to reach their primary endpoint in phase 2 and 3 trials. One of the molecules that is currently studied in phase 3, is the liver-targeted fatty acid synthetic enzyme stearoyl CoA desaturase 1 (SCD1) inhibitor aramchol. In phase 2, positive effects on liver fat content but also on steatohepatitis were observed (7) . There was also a trend, albeit not significant, suggesting a beneficial impact on fibrosis. SCD1 is mainly expressed in hepatocytes, but Bhattacharya et al (8) report on the effects of aramchol in hepatic stellate cells (HSC) in vitro. In primary human HSC, aramchol significantly reduced SCD1 mRNA whilst upregulating peroxisome proliferator-activated receptor (PPAR) gamma. The latter effect was also observed in primary human hepatocytes, highlighting the potential importance of the PPAR pathways (9). This was accompanied by a decrease in expression of several genes implied in fibrogenesis, both at mRNA and protein levels. Experiments with SCD1 knockdown or overexpression in another human HSC cell line further support the role of SCD1 and the effect of aramchol on HSC and fibrosis. This illustrates that aramchol not only targets hepatocytes but also HSC, hence potentially adding a direct anti-fibrotic effect to the overall action on NASH. Although this proof of efficacy needs to be delivered by the currently J o u r n a l P r e -p r o o f ongoing phase 3, these data provide at least further rationale to study aramchol as a treatment for NASH and fibrosis.
NAFLD excludes by definition the consumption of a relevant amount of alcohol, making the diagnosis exclusionary, but in real life, several causes of fatty liver disease can co-exist. And whether this then translate into progressive disease, depends, amongst others, on the presence of genetic factors that are sometimes relevant to several causes of chronic liver disease. Bianco et al (10) review genetic polymorphism that play a role in both alcoholic and non-alcoholic fatty liver disease, or their combination, focusing on PNPLA3 and MBOAT7, with an emphasis on how these genetic variants impact on disease pathophysiology. They also take a deep dive into the role of interleukin 32, emerging as a key regulator of obesitydriven inflammation and further highlighting the importance of the adipose-tissue liver axis, particularly in NAFLD (4).
As also mentioned in the paper by Bianco et al (10) there is an ongoing debate about changing the name of NAFLD to a name (and corresponding set of criteria) that better reflects our current understanding of NAFLD as fatty liver disease developing in the context of metabolic derangements. Interestingly, and that is why it is important not to forget the old literature, clinicians already linked fatty liver to problems of overweight, unhealthy macronutrient dietary composition and sedentarism, even in children, long time ago. Such reports already date from the first half of the 19 th century, as elegantly reviewed by Ayonrinde (11) . This puts the current discussion, with claims about novel insights, somewhat in a different historical perspective, and these historical data may aid finding consensus about a new name for the most prevalent chronic liver disease of modern times.
Severe alcoholic hepatitis remains a challenge for treating clinicians and comes with a high mortality rate. Despite intensive research efforts, not so much progress has been made over the last decade. Corticosteroids remain the cornerstone of therapy, but given the potential side effects, a better understanding of disease mechanisms and treatment response could help guiding disease management. Sharma et al (12) examined by RNA-seq the peripheral blood mononuclear cells of 37 patients with severe alcoholic hepatitis, treated with corticosteroids, at baseline and at 7 days, where treatment response was assessed based on the Lille score (13) . Interestingly, the most upregulated gene panels related to the lymphoid lineage and their activity and proliferation (T and B cells and NK cells), rather than myeloid cells, with striking differences at baseline between future responders and non-responders. Furthermore, presence or absence of changes over time in activity of functional gene modules related to innate and adaptive immunity clearly differentiated responders vs. nonresponders. This study hence gives further insight into the immunological mechanisms at play in severe alcoholic hepatitis, but also, if validated in larger cohorts, offers the potential to better select the patients with the best benefit/risk ratio for corticosteroid therapy.
It is well known that hepatocytes within the liver are functionally different according to their zonal distribution. This is important, as for many studies on e.g., gene expression, we rely on tissue homogenates in which zonal differences within the liver are not captured. Also, when we analyse the different cell compartments separately, still we mostly rely on a mixture of cells resulting from a homogenate without zonation. Single cell techniques allow for a more granular approach. Payen et al (14) used a tissue dissociation protocol on freshly explanted human livers. First, they confirmed functional clustering of the hepatocytes, in line with the zonation landmark genes that were previously described and showing their precision. But most notably, HSC also clustered in 2 distinct groups, which they called HSC1 and HSC2. This clustering appeared not to be driven by activation status genes. Based on further analysis and immunostaining on biopsy samples, HSC1 appeared to be localized in the portal and centrolobular areas, whereas the second type was more located around the sinusoids. Further functional characterization showed that first of all both types are the most important contributor cell types for extracellular matrix formation, but furthermore that HSC1 are more involved in glycosaminoglycan metabolism whereas HSC2 have antigen presenting cell properties. This study is hence an important contribution to our understanding of the heterogeneity in liver cell function, especially in HSC, which are key drivers of fibrosis formation and hence disease progression in many chronic liver diseases. Also, in light of the ongoing search for antifibrotic therapies, these findings can significantly contribute to this drug development path. Cellular senescence has shown to be a potentially relevant mechanism in many, and not only age-related, diseases. Cholangiocyte senescence has emerged as an important feature in the pathogenesis of primary sclerosing cholangitis (PSC), for which pharmacotherapy is still an unmet need. The secretome of senescent cells (senescence-associated secretory phenotype) contributes to an altered, pro-inflammatory, microenvironment and is supposed to play a role in inflammation and fibrogenesis. In the current issue of J Hep Reports, Alsuraih et al (15) shed further light on this mechanism and the potential benefit of its pharmacological modulation. They used two novel genetic models to manipulate p16 Ink4a expression in the well-established PSC model of multidrug-resistance 2 (Mdr2)-/-mouse. p16INK4a is highly expressed in senescent cells and plays a role in cell cycle regulation. Genetic removal of p16positive senescent cholangiocytes (by targeted apoptosis) markedly reduced peribiliary inflammation and fibrosis. These and other results from the study by Alsuraih et al (15) clearly support the concept that senescent cholangiocytes play an important role in PSC pathogenesis, and that inhibiting senescence or targeted removal of these senescent cells (senolytic therapy) improves inflammation and fibrosis, suggesting this has potential implications in the clinic. In this same issue, Cazzagon et al (16) provide clinical data that are nicely in line with the exhaustive pre-clinical work of Alsuraih et al (15) . On liver samples of a cohort of 35 PSC patients, they demonstrated that p16 expression in native bile ducts and in ductular reaction correlated with fibrosis, hepatitis activity and bile duct loss. Also, p21, another marker of senescent cholangiocytes, correlated with some of these features, as well as with clinical outcome parameters, further stressing the importance of cholangiocyte senescence and the clinical relevance of the aforementioned preclinical data. Several senolytic compounds have been developed recently. Targeting apoptosis is probably not feasible in patients due to toxicity of the compounds developed so far, but fisetin, a senolytic compound with a flavonoid structure, was shown in the study of Alsuraih et al (15) to be beneficial. As flavonols have a good safety and tolerability profile, this is worthwhile further exploring for its therapeutic potential.
With these and the other papers the current issue of J Hep Reports contains, the editorial team aims at providing our readership with the highest quality innovation in clinical and experimental hepatology, in line with the goals of our journal. Enjoy discovering its content!
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance
Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD
Lifestyle modification in NAFLD/NASH: Facts and figures
Sanyalon behalf of the ARREST investigator study group. One-Year Results of the Global Phase 2b Randomized Placebo-Controlled Arrest Trial of Aramchol, a Stearoyl CoA Desaturase Inhibitor, in Patients with NASH
Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Genetic predisposition similarities between NASH and ASH: identification of new therapeutic targets
Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD – Reconciling the present with the past
Differential blood transcriptome modules predict response to corticosteroid therapy in alcoholic hepatitis
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of alcoholrelated liver disease
Single-cell RNA sequencing of human liver reveals hepatic stellate cell heterogeneity
Genetic or pharmacological reduction of cholangiocyte senescence improves inflammation and fibrosis in the Mdr2-/- mouse
Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis